What is Immunic?
Immunic is a biotherapeutic organization that has historically focused on the development of advanced cell-based therapies, most notably the ELAD System. Designed as a bio-artificial liver, the ELAD platform aimed to address the critical medical needs of patients suffering from severe acute liver failure. The company's operational history is defined by rigorous clinical testing and pilot manufacturing, reflecting a commitment to pioneering complex medical solutions.
Following the results of its Phase 3 clinical trials, which did not meet primary endpoints, the company underwent a significant strategic pivot. This transition involved a reduction in workforce and a cessation of development for the ELAD System in major markets. Currently, Immunic is positioned as an entity focused on the evaluation of strategic alternatives, including the potential divestiture of its intellectual property and remaining assets, as it seeks to maximize value for its shareholders.
How much funding has Immunic raised?
Immunic has raised a total of $63.7M across 3 funding rounds:
Series A
$19.7M
Share Placement
$15M
Debt
$29M
Series A (2016): $19.7M with participation from High-Tech Gru00fcnderfonds, Bayern Kapital, Life Sciences Partners, and LifeCarePartners
Share Placement (2020): $15M led by Altium Capital Limited
Debt (2020): $29M supported by The European Investment Bank
Key Investors in Immunic
The European Investment Bank
Established in 1958 and headquartered in Luxembourg, European Investment Bank (EIB) is the European Union's nonprofit long-term lending and finance institution.
Bayern Kapital
Bayern Kapital is a leading venture capital investor in Bavaria, focusing on innovative, technology-oriented startups and companies across various sectors including High-Tech, DeepTech, and Life Sciences.
Life Sciences Partners
A prominent European venture capital firm specializing in life sciences, focusing on early-to-late stage investments in biotechnology and medical technology companies.
What's next for Immunic?
The path forward for Immunic is centered on the systematic assessment of strategic alternatives. Having moved away from active clinical development, the company is now prioritizing the monetization of its existing assets and intellectual property portfolio. This phase of the corporate lifecycle is critical, as the firm seeks to leverage its historical research and development efforts to provide a return on the capital provided by its institutional backers.
Investors and market observers are closely watching the company's efforts to identify potential buyers or partners who may find value in the underlying technology or the company's remaining infrastructure. The focus remains on disciplined capital management and the execution of a structured exit or reorganization strategy, ensuring that all remaining resources are utilized to navigate the current market environment effectively.
